Syndax Pharmaceuticals, Inc. (SNDX)
Nasdaq: SNDX · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2007
Who owns Syndax Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
5
Kynam Capital Management, LP holds 9.98% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G/A filed Feb 14, 2025 says.
Directors and officers
10
report now, of 28 people on the record since 2016. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Kynam Capital Management, LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.0001 per share
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 17, 2025 · Common Stock
Goldman Sachs Group Inc.
SCHEDULE 13G/A · filed Aug 13, 2025 · Common Stock · 5.2% in May 9, 2025
State Street Corporation
SCHEDULE 13G · filed Aug 7, 2026 · COMMON STOCK · 5.3% in Feb 9, 2026
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
Morgan Stanley
SCHEDULE 13G/A · filed May 7, 2025 · Common Stock · reported falling below 5%, from 6.3% in Feb 5, 2025
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5% in Aug 18, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 7.16% in Jan 30, 2026
Wellington Management Group LLP
SCHEDULE 13G/A · filed Mar 7, 2025 · Common Stock · reported falling below 5%
What SNDX reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Cowen and Company L L C
An entity · legal entity · owns, named in the 10-K filed Feb 26, 2026
1 subsidiary in 1 country, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
10sales
0purchases
4sales on a scheduled plan
4people selling
$2.9Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 48 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer | 4 | $1.4M | 1 | 0 | $0 |
| Botwood Nicholas A.J. | Head of R&D, CMO | 2 | $1.2M | 2 | 0 | $0 |
| Goldan Keith A. | Chief Financial Officer | 3 | $100,000 | 0 | 0 | $0 |
| Podlesak Dennis | director | 1 | $100,000 | 1 | 0 | $0 |